Fiche traitement
Disease-Modifying Therapy
Fudan University • Alzheimer
Suivi actif
À vérifier
Résumé
Disease-Modifying Therapy est développé par Fudan University. Le traitement est actuellement en À vérifier. Il est associé à Alzheimer. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.
À vérifier
À vérifier
À vérifier
Fudan University
China
The goal of this multicenter retrospective observational study is to learn about the real-world safety and clinical effectiveness of disease-modifying therapy (DMT) in adults with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or AD dementia. The main questions it aims to answer are:
What are the safety outcomes of DMT, including amyloid-related imaging abnormalities (ARIA), adverse events, and infusion reactions (IRRs)? How do Clinical Dementia Rating (CDR) measures change in patients who receive DMT compared with those who do not?
Researchers will compare patients who receive DMT as part of their routine clinical care with patients who do not receive DMT to evaluate differences in clinical outcomes and safety.
Participants will not receive any study-assigned intervention or additional treatment as part of this study. Researchers will retrospectively collect existing clinical data, including cognitive and neuropsychiatric assessments, imaging findings, biomarker results, DMT use, and safety information.
2026-11-03
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
À vérifier
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
À vérifier
Confiance automatique : 0%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT07923812, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-11-03
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeÀ vérifier
Études associées1
Publications associées21
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
25 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2026-07-08 | PublicationHydroxyurea Promotes Brain Development in Children with Sickle Cell Anemia. | Brain research bulletin |
| 2026-07-10 | PublicationThe Role of Sphingosine-1-Phosphate Signaling in Cerebral Ischemia/Reperfusion Injury and Alzheimer's Disease Pathology. | International journal of molecular sciences |
| 2026-07-18 | PublicationEffects of respiratory muscle training on respiratory function in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. | Journal of neurology |
| 2026-07-22 | PublicationFrom Molecular Pathophysiology to Clinical Trial Design in Sjögren's Disease: A Three-Axis Framework. | International journal of molecular sciences |
| 2026-08-08 | PublicationDifferential safety profiles of disease-modifying therapies in MS: Age- and sex-based analysis from a real-world cohort. | Multiple sclerosis and related disorders |
| 2026-08-13 | PublicationBrain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson's disease. | Neural regeneration research |
| 2026-08-13 | PublicationA Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator. | Movement disorders : official journal of the Movement Disorder Society |
| 2026-08-13 | PublicationCoordinated oxidative shift during relapse and recovery in multiple sclerosis: A paired analysis of multiple biomarkers. | Journal of neuroimmunology |
| 2026-08-13 | PublicationThe Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy. | Trials |
| 2026-08-13 | PublicationSafety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis. | BMC neurology |
| 2026-08-13 | PublicationNatalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. | Health technology assessment (Winchester, England) |
| 2026-08-16 | PublicationThe TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants. | Contemporary clinical trials |
| 2026-08-16 | PublicationA multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |
| 2026-08-16 | PublicationSevere autoimmune hepatitis and necrotising pancreatitis following ofatumumab in a patient with multiple sclerosis. | BMJ case reports |
| 2026-08-16 | PublicationImmunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis. | Multiple sclerosis and related disorders |
| 2026-08-16 | PublicationEffects of alpha-lipoic acid in non-alcoholic fatty liver disease (NAFLD): a systematic review of literature. | Journal of diabetes and metabolic disorders |
| 2026-08-16 | PublicationLongitudinal evolution of JC virus serological index in multiple sclerosis patients treated with natalizumab: Observational dynamics in a decade-spanning real-world cohort (2014-2024). | Clinical neurology and neurosurgery |
| 2026-08-16 | PublicationOzanimod: A Review in Relapsing Forms of Multiple Sclerosis. | CNS drugs |
| 2026-09-20 | PublicationPharmacological treatment of cardiogenic shock. | Current opinion in critical care |
| 2026-10-11 | PublicationExercise treadmill testing for efficacy evaluation in randomized, controlled trials. | American heart journal |
| 2026-10-25 | PublicationEfficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet (London, England) |
| 2026-10-26 | Début de l’étudeNCT07923812 | Registre d’essai clinique |
| 2026-11-03 | Dernière mise à jour des donnéesDisease-Modifying Therapy | Biomedical Watch |
| 2026-11-08 | Création de l’enregistrementNCT07923812 | Registre d’essai clinique |
| 2027-12-31 | Fin de l’étude prévue / enregistréeNCT07923812 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT07923812 | ROOT-AD — Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study | À vérifier | RECRUITING | China | Fudan University |
Publications liées
21 publication(s)Publications liées
21 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial. Voir source | 42805227 | 10.1016/S0140-6736(26)01599-0 | Lancet (London, England) | |
| Exercise treadmill testing for efficacy evaluation in randomized, controlled trials. Voir source | 41687797 | 10.1016/j.ahj.2026.107379 | American heart journal | |
| Pharmacological treatment of cardiogenic shock. Voir source | 42273963 | 10.1097/MCC.0000000000001393 | Current opinion in critical care | |
| The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants. Voir source | 41135813 | 10.1016/j.cct.2025.108117 | Contemporary clinical trials | |
| A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis. Voir source | 40775552 | 10.1007/s10072-025-08377-3 | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | |
| Severe autoimmune hepatitis and necrotising pancreatitis following ofatumumab in a patient with multiple sclerosis. Voir source | 41526077 | 10.1136/bcr-2025-269312 | BMJ case reports | |
| Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis. Voir source | 42413316 | 10.1016/j.msard.2026.107373 | Multiple sclerosis and related disorders | |
| Effects of alpha-lipoic acid in non-alcoholic fatty liver disease (NAFLD): a systematic review of literature. Voir source | 42368730 | 10.1007/s40200-026-01979-4 | Journal of diabetes and metabolic disorders | |
| Longitudinal evolution of JC virus serological index in multiple sclerosis patients treated with natalizumab: Observational dynamics in a decade-spanning real-world cohort (2014-2024). Voir source | 42229340 | 10.1016/j.clineuro.2026.109522 | Clinical neurology and neurosurgery | |
| Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis. Voir source | 39368032 | 10.1007/s40263-024-01116-w | CNS drugs | |
| Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson's disease. Voir source | 38989947 | 10.4103/NRR.NRR-D-24-00187 | Neural regeneration research | |
| A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator. Voir source | 37195859 | 10.1002/mds.29346 | Movement disorders : official journal of the Movement Disorder Society | |
| Coordinated oxidative shift during relapse and recovery in multiple sclerosis: A paired analysis of multiple biomarkers. Voir source | 42470870 | 10.1016/j.jneuroim.2026.579030 | Journal of neuroimmunology | |
| The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy. Voir source | 41361285 | 10.1186/s13063-025-09254-2 | Trials | |
| Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis. Voir source | 41420217 | 10.1186/s12883-025-04514-9 | BMC neurology | |
| Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. Voir source | 42579606 | 10.3310/GJHT1811 | Health technology assessment (Winchester, England) | |
| Differential safety profiles of disease-modifying therapies in MS: Age- and sex-based analysis from a real-world cohort. Voir source | 42107470 | 10.1016/j.msard.2026.107220 | Multiple sclerosis and related disorders | |
| From Molecular Pathophysiology to Clinical Trial Design in Sjögren's Disease: A Three-Axis Framework. Voir source | 42449965 | 10.3390/ijms27135692 | International journal of molecular sciences | |
| Effects of respiratory muscle training on respiratory function in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Voir source | 42455190 | 10.1007/s00415-026-13982-z | Journal of neurology | |
| The Role of Sphingosine-1-Phosphate Signaling in Cerebral Ischemia/Reperfusion Injury and Alzheimer's Disease Pathology. Voir source | 42352925 | 10.3390/ijms27125200 | International journal of molecular sciences | |
| Hydroxyurea Promotes Brain Development in Children with Sickle Cell Anemia. Voir source | 42413789 | 10.1016/j.brainresbull.2026.112034 | Brain research bulletin |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-11-03
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.